Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease

Journal of Clinical Gastroenterology

Volumn 36, Issue 3, 2003, Pages 234-237

  Rulyak, Stephen J ^a   Saunders, Michael D ^a   Lee, Scott D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Azathioprine; Crohn's disease; Hepatotoxicity; Inflammatory bowel diseases

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOTRANSFERASE; AZATHIOPRINE; INFLIXIMAB; LIVER ENZYME; MERCAPTOPURINE; TIOGUANINE;

ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CROHN DISEASE; CYTOTOXICITY; DISEASE EXACERBATION; DYSPNEA; ENTERITIS; FEMALE; HUMAN; HYPOTENSION; IMMUNOMODULATION; LIVER INJURY; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; VOMITING;

6-MERCAPTOPURINE; ADULT; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; CROHN DISEASE; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; THIOGUANINE;

EID: 0037370693     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200303000-00010     Document Type: Article

References (35)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: A long-term, randomized, double blind study. N Engl J Med 1980;302:981-7.
2. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
3. Willoughby JMT, Kumar PJ, Beckett J, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;731:944-7.
4. Obrien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101:39-46.
5. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis. Ann Intern Med 1995;123:132-42.
6. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. BMJ 1974;4:627-30.
7. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of ulcerative colitis. Gastroenterology 1975;69:96-9.
8. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
9. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine n the management of inflammatory bowel disease: Short- and long-tern toxicity. Ann Intern Med 1989;111:641-9.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
11. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
12. Dubinsky MC, Hassard PV, Abreu MT, et al. Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine [abstract]. Gastroenterology 2000;118:A891.
13. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-9.
14. Sandbom WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
15. Murphy ML, Tank TC, Ellison RR, et al. Clinical evaluation of chloropurine and thioguanine. Proc Am Assoc Cancer Res 1955;2:36-9.
16. Hales DR, Jerner RW, Hall BE, et al. Comparison of therapeutic effects of 6-methyl mercaptopurine, 6-chloropurine, 6-thioguanine, and 6-mercaptopurine in human acute leukemia. Clin Res Proc 1957;4:32.
17. Lewis JP, Unman JW, Marshall GJ, et al. Randomized clinical trial of cytosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia. Cancer 1977:39:1387-96.
18. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia. Br J Cancer 1993:68:186-90.
19. Spiers AS, Kaur J, Galton DAG, et al. Thioguanine as primary treatment following chronic granulocytic leukemia. Lancet 1975;1:829-33.
20. Zackheim HS, Glogau A, Fisher DA. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8.
21. Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 1999;135:433-7.
22. Mason C, Krueger GG. Thioguanine for refractory psoriasis: A 4-year experience. J Am Acad Dermatol 2001;44:67-72.
23. Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 1976:85:578-82.
24. Krivoy N, Raz R, Carter A, et al. Reversible hepatic veno-occlusive disease and 6-thioguanine [letter]. Ann Intern Med 1982;96:788.
25. Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol 1982;35:1086-91.
26. D'Cruz CA, Wimmer RS, Harcke HT, et al. Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia. Cancer 1983;52:1803-7.
27. Gill RA, Onstad GR, Cardamone JM, et al. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982;96:58-60.
28. Kao NL, Rosenblate HJ. 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 1993;28:1017-8.
29. Murphy FP, Coven TR, Burack LH, et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol 1999;135:1495-502.
30. Key NS, Kelly PM, Emerson PM, et al. Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia. Lancet 1987;2:1050-2.
31. Larrey D, Freneaux E, Berson A, et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988:29:1265-9.
32. Kitchen BJ, Balis FM, Poplack DG, et al. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res 1997;3:713-7.
33. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993;68:186-90.
34. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
35. Kitchen BJ, Moser A, Lowe E, et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther 1999;291:870-4.